Navigation Links
FDA Approves New Treatment for People With COPD
Date:8/1/2014

FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with the progressive, deadly respiratory ailment known as chronic obstructive pulmonary disease (COPD) have a new weapon to battle the disease, the U.S. Food and Drug Administration said Thursday.

The agency approved a new treatment, an inhaled spray called Striverdi Respimat (olodaterol) for COPD, the third leading killer of Americans. COPD, which is often linked to smoking, involves multiple lung conditions such as chronic bronchitis and emphysema.

Patients with COPD may experience a number of symptoms, such as wheezing, coughing and tightness in their chest. According to the FDA, Striverdi Respimat belongs to a class of medicines known as long-acting beta-adrenergic agonists (LABAs).

The agency said the drug works by helping the airway muscles in the lungs stay relaxed, and it can be taken once daily over a prolonged period of time.

"The availability of this new long-term maintenance medication provides an additional treatment options for the millions of Americans who suffer with COPD," Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

The FDA evaluated the safety and effectiveness of Striverdi Respimat compared to a placebo in more than 3,100 people diagnosed with COPD. Those who took the medication had improved lung function.

Commonly reported side effects of Striverdi Respimat include runny nose, coughs, dizziness and upper respiratory tract infections, among others.

Striverdi Respimat is not approved for people with asthma, and asthma patients should not use it, the FDA warned. That's because the drug raises the risk of asthma-related death. This inhalation spray should also never be used to treat breathing problems that develop suddenly, the agency cautioned.

People with COPD that is progressing rapidly should also not take Striverdi Respimat, the FDA added. For these patients, the medication could lead to heart problems and the narrowing or blockage of the airway, they explained.

More information

The U.S. National Heart, Lung, and Blood Institute provides more information on COPD treatments.

SOURCE: U.S. Food and Drug Administration, news release, July 31, 2014.

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
8. FDA Approves New Once-a-Day HIV Pill
9. FDA Approves New Type of Flu Vaccine
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves 1st Skin Patch to Combat Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves New Treatment for People With COPD
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... emergency and now estimates that there could be four million Zika-related cases in the ... to date with numbers of US cases reported per year skyrocketing to an estimated ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... oxygen therapy devices market to grow at a CAGR of 10.16% ... Therapy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... BOSTON , March 23, 2017 ... respond optimally to most vaccines because their young ... researchers at Boston Children,s Hospital report achieving strong ... the final preclinical model before human trials — ... the immune response. In two simultaneous papers, they ...
Breaking Medicine Technology: